Dr. Neeta Somaiah, MD
Claim this profileM D Anderson Cancer Center
Studies Soft Tissue Sarcoma
Studies Cancer
9 reported clinical trials
13 drugs studied
Area of expertise
1Soft Tissue Sarcoma
Stage IV
Stage III
FGFR positive
2Cancer
Stage IV
Stage III
FGFR positive
Affiliated Hospitals
Clinical Trials Neeta Somaiah, MD is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
Oleclumab + Durvalumab
for Advanced Sarcoma
This trial is testing two immunotherapy drugs, oleclumab and durvalumab, in patients with difficult-to-treat sarcoma. These drugs help the immune system to find and destroy cancer cells and may stop the cancer from growing and spreading.
Recruiting1 award Phase 210 criteria
More about Neeta Somaiah, MD
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Neeta Somaiah, MD has experience with
- Regorafenib
- T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
- Durvalumab
- Oleclumab
- Sintilimab
- Anlotinib
Breakdown of trials Neeta Somaiah, MD has run
Soft Tissue Sarcoma
Cancer
Uterine Tumors
Gastrointestinal Stromal Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neeta Somaiah, MD specialize in?
Neeta Somaiah, MD focuses on Soft Tissue Sarcoma and Cancer. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Neeta Somaiah, MD currently recruiting for clinical trials?
Yes, Neeta Somaiah, MD is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Neeta Somaiah, MD has studied deeply?
Yes, Neeta Somaiah, MD has studied treatments such as Regorafenib, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy, Durvalumab.
What is the best way to schedule an appointment with Neeta Somaiah, MD?
Apply for one of the trials that Neeta Somaiah, MD is conducting.
What is the office address of Neeta Somaiah, MD?
The office of Neeta Somaiah, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.